Brightgene Bio-medical Technology Co (SHSE:688166) Research & Development: ¥363 Mil (TTM As of Mar. 2026)


SHSE:688166 Brightgene Bio-medical Technology Co Ltd SHSE:688166
84 GF Score
Price ¥31.19
GF Value ¥38.49
Valuation Modestly Undervalued
! 7 Warning Signs
View Full Analysis

What is Brightgene Bio-medical Technology Co Research & Development?

Brightgene Bio-medical Technology Co SHSE:688166 +4.66% 84 Research & Development is ¥363 Mil as of Mar. 2026. GuruFocus rates SHSE:688166 with a GF Score™ of 84/100 and a GF Value™ of ¥38.49 (Modestly Undervalued). The stock has 7 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Brightgene Bio-medical Technology Co's Research & Development for the three months ended in Mar. 2026 was ¥120 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 was ¥363 Mil.

Brightgene Bio-medical Technology Co  (SHSE:688166) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Brightgene Bio-medical Technology Co Research & Development Related Terms

Brightgene Bio-medical Technology Co Research & Development Historical Data

* Premium members only.

The historical data trend for Brightgene Bio-medical Technology Co's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Brightgene Bio-medical Technology Co Research & Development Chart

Brightgene Bio-medical Technology Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 173.29 207.03 248.59 297.45 304.95

Brightgene Bio-medical Technology Co Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 61.64 76.65 78.14 88.52 120.15
SHSE:688166
84GF Score
Brightgene Bio-medical Technology Co Ltd SHSE:688166
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Brightgene Bio-medical Technology Co Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥363 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of ¥363 Mil mean?
Brightgene Bio-medical Technology Co (SHSE:688166) has a Research & Development of ¥363 Mil as of Mar. 2026. Research and development expense is the total cost for research and development activities. View historical data on Brightgene Bio-medical Technology Co and its competitors.
Is Brightgene Bio-medical Technology Co's Research & Development too high?
Brightgene Bio-medical Technology Co's current Research & Development is ¥363 Mil. Overall, Brightgene Bio-medical Technology Co has a GF Score™ of 84/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Brightgene Bio-medical Technology Co's Research & Development compare to VRTX and REGN?
Brightgene Bio-medical Technology Co's Research & Development of ¥363 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Biotechnology company?
A good Research & Development depends on the Biotechnology industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Brightgene Bio-medical Technology Co and its competitors. Brightgene Bio-medical Technology Co's current Research & Development is ¥363 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Brightgene Bio-medical Technology Co stock overvalued right now?
Based on GuruFocus' analysis, Brightgene Bio-medical Technology Co (SHSE:688166) is currently considered Modestly Undervalued. The stock's GF Value™ is ¥38.49, compared to a current price of ¥31.19 — trading 19% below its estimated fair value. The current Research & Development is ¥363 Mil. Brightgene Bio-medical Technology Co's overall GF Score™ is 84/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Brightgene Bio-medical Technology Co (SHSE:688166), the current Research & Development is ¥363 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Brightgene Bio-medical Technology Co (SHSE:688166) Overvalued in 2026?

Based on GuruFocus' analysis, Brightgene Bio-medical Technology Co stock appears to be undervalued. The current stock price of ¥31.19 is trading 19% below its estimated GF Value™ of ¥38.49. GuruFocus considers Brightgene Bio-medical Technology Co to be Modestly Undervalued.

Key valuation signals for SHSE:688166:

  • Research & Development: ¥363 Mil
  • GF Value™: ¥38.49 vs. price of ¥31.19 (19% below fair value)
  • GF Score™: 84/100 with 7 warning signs

No single metric tells the full story. See the SHSE:688166 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Brightgene Bio-medical Technology Co Business Description

Address No. 218 Xinghu Street, Buildings C25-C28, Nanotechnology Park, Suzhou Industrial Park, Jiangsu Province, Suzhou, CHN, 215123
Brightgene Bio-medical Technology Co Ltd is engaged in the Research and development and production of pharmaceutical intermediates, active pharmaceutical ingredients and formulations with high technological barriers.
84GF Score

Get the complete analysis for SHSE:688166

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

¥31.19
Price
¥38.49
GF Value